Analgesic nephropathy screening: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Analgesic nephropathy}} {{CMG}} {{AE}} {{SHA}} ==Overview== There is insufficient evidence to recommend routine screening for analgesic nephropathy. ==Screening=..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for analgesic nephropathy. | There is insufficient evidence to recommend routine [[Screening (medicine)|screening]] for analgesic nephropathy. | ||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for analgesic nephropathy. | There is insufficient evidence to recommend routine [[Screening (medicine)|screening]] for analgesic nephropathy. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 13:31, 6 July 2020
|
Analgesic nephropathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Analgesic nephropathy screening On the Web |
|
American Roentgen Ray Society Images of Analgesic nephropathy screening |
|
Risk calculators and risk factors for Analgesic nephropathy screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
There is insufficient evidence to recommend routine screening for analgesic nephropathy.
Screening
There is insufficient evidence to recommend routine screening for analgesic nephropathy.